Salivary and peri-implant crevicular fluid biomarkers promising predictors of peri-implant disease conditions: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-13 20:45 GMT   |   Update On 2024-03-14 04:02 GMT
Advertisement

Lithuania: A recent systematic review published in The International Journal of Oral & Maxillofacial Implants assessed the recent evidence (2017–2022) to identify salivary and peri-implant crevicular fluid biomarkers with potential prognostic and diagnostic capabilities for peri-implant disease conditions. 

The study found that of all 49 biomarkers evaluated, IL-1β and RANKL were promising as biomarkers of peri-implant disease conditions; however, the researchers suggest the need for clinical studies with a robust methodology to strengthen the evidence base.

Advertisement

"RANKL and IL-1β have the highest diagnostic significance in assessing peri-implant inflammatory conditions, as differences were observed between all three groups (HI < PIM < PI), the researchers wrote.

The study was conducted by Vykintas Pliavga, Lithuanian University of Health Sciences, Kaunas, Lithuania, and colleagues to summarize the latest scientific literature regarding the concentrations of biomarkers in saliva and peri-implant crevicular fluid (PICF) of healthy implant (HI) patients and patients with peri-implant mucositis (PIM) and peri-implantitis (PI).

For this purpose, the researchers performed a literature review according to PRISMA guidelines. The following online databases were used: ScienceDirect, PubMed MEDLINE, and Cochrane Library. A combination of keywords was used, and selection criteria were applied. Selected articles were published between 2017 and 2022, written in English, and conducted in humans. The articles investigated the levels of saliva and PICF biomarkers in peri-implantitis patients and compared them to healthy implant/peri-implant mucositis patients.

The researchers selected 16 publications comprising 1,117 patients with 1,346 implants.

Following were the key findings:

  • Qualitative analysis revealed 49 different biomarkers, the levels of which were compared between groups.
  • After evaluating the most frequently studied biomarkers, significantly higher values of IL-1β, RANKL, sRANKL, IL-6, TNF-α, TNFSF12, MMP2, and MMP8 levels were observed in the PI group than in the HI group.
  • Of the above-listed biomarkers, IL-1β and RANKL demonstrated the highest diagnostic significance as their levels differed among the three groups, with the highest levels in the peri-implantitis group, followed by the peri-implant mucositis group and the lowest levels in the healthy group.

"Of the 49 biomarkers evaluated, RANKL and IL-1β have potentially the highest diagnostic significance in assessing peri-implant inflammatory conditions, as differences were observed between all three groups (HI < PIM < PI), but data from current publications were not adequate to provide strong evidence," the researchers concluded.

Reference:

Pliavga V, Peceliunaite G, Daugela P, Leketas M, Gervickas A, Juodzbalys G. Peri-implantitis Diagnosis and Prognosis Using Biomarkers: A Systematic Literature Review. Int J Oral Maxillofac Implants. 2023 Dec 12;38(6):1095-1105. doi: 10.11607/jomi.10353. PMID: 38085740.


Tags:    
Article Source : The International Journal of Oral & Maxillofacial Implants

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News